Cover Image
市場調查報告書

中耳炎:開發中產品分析

Otitis Media - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232857
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
中耳炎:開發中產品分析 Otitis Media - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 82 Pages
簡介

中耳炎的症狀有耳朵疼痛,睡眠困難,平衡感覺障礙,發熱,頭痛,食慾不振等。這個疾病患病的風險要素有高齡化,季節要素,香煙及曝露於嚴重的大氣污染等。

本報告提供全球開發平台中的中耳炎治療藥概要,提供您目前開發平台狀況和最新趨勢,後期階段及中止計劃的資訊,主要企業及他們開發中的產品評估等。

簡介

  • 調查範圍

中耳炎概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

中耳炎:企業開發中的治療藥

中耳炎:大學/機關研究中的治療藥

中耳炎:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

中耳炎:企業開發中的產品

中耳炎:大學/機關研究中的產品

中耳炎的治療藥的開發企業

  • GlaxoSmithKline plc
  • Cubist Pharmaceuticals, Inc.
  • Yuhan Corporation
  • Arbor Pharmaceuticals, LLC.
  • Otonomy, Inc.
  • Cellceutix Corporation
  • Serum Institute of India Limited
  • ContraFect Corporation
  • BCO Pharma Ltd
  • Otitis Media

中耳炎:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ciprofloxacin SR
  • AR-01
  • GSK-2189242A
  • betahistine hydrochloride
  • SIILPCV-10
  • P-13
  • brilacidin
  • solithromycin
  • Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections
  • BCO-002
  • YH-1177
  • CF-309

中耳炎:最近的開發平台趨勢

中耳炎:暫停中的計劃

中耳炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8962IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Otitis Media - Pipeline Review, H1 2017, provides an overview of the Otitis Media (Ear Nose Throat Disorders) pipeline landscape.

Otitis media (OM) is any inflammation of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain, difficulty sleeping, loss of balance, fever, headache and loss of appetite. Risk factors include age, seasonal factors and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrine.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Otitis Media - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Otitis Media (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Otitis Media (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 2, 4 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Otitis Media (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Otitis Media (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Otitis Media (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Otitis Media (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Otitis Media (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Otitis Media (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Otitis Media - Overview
  • Otitis Media - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Otitis Media - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Otitis Media - Companies Involved in Therapeutics Development
  • Cellceutix Corp
  • ContraFect Corp
  • GlaxoSmithKline Plc
  • Lee's Pharmaceutical Holdings Ltd
  • Madam Therapeutics BV
  • Merck & Co Inc
  • MerLion Pharmaceuticals Pte Ltd
  • Otonomy Inc
  • Yuhan Corp
  • Otitis Media - Drug Profiles
  • (cholesteryl palmitate + colfosceril palmitate) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (dexamethasone acetate + piperacillin sodium + tazobactam sodium) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • betahistine dihydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • brilacidin tetrahydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CF-303 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CF-309 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ciprofloxacin hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ciprofloxacin hydrochloride SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • finafloxacin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GSK-2189242A - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pazufloxacin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PCL-1440 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pneumococcal (23-valent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Otitis Media - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • solithromycin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Otitis Media - Dormant Projects
  • Otitis Media - Product Development Milestones
  • Featured News & Press Releases
  • Nov 02, 2016: Otonomy Announces Assignment of J Code for OTIPRIO
  • Oct 07, 2016: Otonomy Holds Investor and Analyst Day and Provides Corporate Update
  • Oct 04, 2016: Otonomy Successfully Completes Phase 2 Clinical Trial of OTIPRIO in Pediatric Patients with Acute Otitis Media with Tympanostomy Tubes
  • Sep 15, 2016: Otonomy Successfully Completes Open-Label Clinical Trial for OTIPRIO in Patients with History of Otitis Media Requiring Tympanostomy Tubes
  • May 20, 2016: Otonomy Announces Assignment of C Code and Pass-Through Payment Status for OTIPRIO
  • May 16, 2016: Otonomy Announces OTIPRIO Data Presentation and Symposium at Combined Otolaryngology Spring Meetings
  • Mar 18, 2016: Otonomy Announces Publication of OTIPRIO Phase 3 Clinical Trial Results in JAMA Otolaryngology
  • Mar 03, 2016: Otonomy Initiates Phase 2 Clinical Trial of OTIPRIO in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
  • Mar 02, 2016: Otonomy Announces Commercial Availability of OTIPRIO
  • Dec 11, 2015: Otonomy Announces FDA Approval of OTIPRIO for the Treatment of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery
  • Nov 03, 2015: Otonomy Initiates Open-Label Clinical Trial for OTIPRIO in Pediatric Patients With History of Otitis Media Requiring Tympanostomy Tubes
  • Sep 24, 2015: Otonomy to Present Results for AuriPro Phase 3 Clinical Trials at 2015 AAO-HNSF Annual Meeting
  • May 07, 2015: Otonomy Completes Enrollment in Phase 2 Clinical Trial for AuriPro in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
  • Apr 28, 2015: Otonomy Announces FDA Acceptance of AuriPro New Drug Application
  • Apr 27, 2015: Otonomy Presents AuriPro Phase 3 Results at American Society of Pediatric Otolaryngology Conference
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Otitis Media, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Otitis Media - Pipeline by Cellceutix Corp, H1 2017
  • Otitis Media - Pipeline by ContraFect Corp, H1 2017
  • Otitis Media - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Otitis Media - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
  • Otitis Media - Pipeline by Madam Therapeutics BV, H1 2017
  • Otitis Media - Pipeline by Merck & Co Inc, H1 2017
  • Otitis Media - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2017
  • Otitis Media - Pipeline by Otonomy Inc, H1 2017
  • Otitis Media - Pipeline by Yuhan Corp, H1 2017
  • Otitis Media - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Otitis Media, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top